Treatment options for central retinal artery occlusion

Area of Science:

• Ophthalmology
• Vascular Neurology

Background:

• Central retinal artery occlusion (CRAO) is an ocular emergency with profound vision loss, sharing risk factors with stroke and heart disease.
• CRAO management aims to restore vision and mitigate risks of further vascular events, including cerebral stroke.
• Existing therapies like carbogen inhalation and vasodilators have not definitively altered CRAO's natural history.

Purpose of the Study:

• To review current understanding and management principles for Central Retinal Artery Occlusion (CRAO).
• To evaluate the efficacy and risks of emerging treatments, including thrombolytic therapy.
• To emphasize the critical time window for effective CRAO intervention.

Main Methods:

• Review of existing literature on Central Retinal Artery Occlusion (CRAO) treatments.
• Analysis of observational studies and randomized controlled trials on thrombolytic therapy (intravenous and intra-arterial).
• Discussion of established and experimental therapeutic approaches for CRAO.

Main Results:

• Traditional CRAO treatments have shown limited efficacy in altering disease outcomes.
• Thrombolytic therapy, while showing potential in observational studies, has not been proven effective in recent randomized trials.
• Intra-arterial thrombolysis carries risks of hemorrhage, and intravenous tissue plasminogen activator (tPA) is not effective beyond 24 hours.

Conclusions:

• Effective treatment for CRAO likely requires intervention within a critical time window, estimated at 6 hours from symptom onset.
• While no definitive treatment exists, CRAO management should mirror other vascular ischemic diseases: rapid reperfusion and early secondary prevention.
• Further research is needed to establish effective and safe treatments for Central Retinal Artery Occlusion.